MSD has decided to abandon the development of its anti-TIGIT antibody vibostolimab and anti-LAG-3 antibody favezelimab, blowing a hole in its immuno-oncology pipeline. The demise of the two programmes ...
Shares in Immutep have leapt after the biotech reported phase 2b results showing that LAG-3 inhibitor eftilagimod alfa (efti) significantly boosted the efficacy of MSD’s Keytruda in patients with ...
Correspondence to Professor Dina C(Christa) Janse van Rensburg, Faculty of Health Science, Section Sports Medicine & Sport Exercise Medicine and Lifestyle Institute (SEMLI), University of Pretoria, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results